TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Effect of θ Burst Magnetic Stimulation on Clinical Symptoms of Alzheimer Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject diagnosed with early Alzheimer's disease or related diseases according to NINCDS-ACDRADA criteria.~* Subjects must have a MMSE score between 10 and 27,indicating mild cognitive impairment or dementia~* CDR score ≤ 2~* Subject under treatment by IAChE for at least 3 Weeks.~* psychotropic treatments are tolerated if they were administered and unchanged for at least 3 months~Exclusion Criteria:~* CDR \> 2~* Any history or clinical signs of other severe psychiatric illnesses (like major depression,psychosis or obsessive compulsive disorder).~  - Page 5 of 6 \[DRAFT\] -~* History of head injury,stroke,or other neurologic disease.~* Organic brain defects on T1 or T2 images.~* History of seizures or unexplained loss of consciousness.~* Implanted pacemaker,medication pump,vagal stimulator,deep brain stimulator.~* Family history of medication refractory epilepsy.~* History of substance abuse within the last 6 months.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- TBS Group (Type: EXPERIMENTAL): On the basis of drug treatment, a course of TBS treatment is performed every three months and 4 courses of treatment a year.
- Drug Group (Type: PLACEBO_COMPARATOR): Stable doses of cholinesterase inhibitors for the treatment and primary care guidance.Once every 3 months follow-up.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Diclofenac Capsules to Treat Pain Following Bunionectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is male or female between 18 and 65 years of age~* For women of child-bearing potential: a woman who is not pregnant and not nursing, and who is practicing an acceptable method of birth control~* Has undergone primary, unilateral, first metatarsal bunionectomy with no additional collateral procedures~* Patient must be willing to stay at the study site ≥ 72 hours~Exclusion Criteria:~* Patient has hypersensitivity, allergy, or clinically significant intolerance to any medications to be used in the study, or related drugs~* Patient has a current disease or history of a disease that will impact the study or the patient's well-being~* Patient has used or intends to use any of the medications that are prohibited by the protocol~* Patient has a history of drug or alcohol abuse or dependence, or patient has a positive urine drug screen or alcohol breathalyzer test~* Patient has taken another investigational drug within 30 days prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Diclofenac Test (lower dose) (Type: EXPERIMENTAL): None
- Diclofenac Test (upper dose) (Type: EXPERIMENTAL): None
- Celecoxib (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Docetaxel Monotherapy or DOXIL and Docetaxel in Patients With Advanced Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Females with locally advanced or metastatic breast cancer who received prior anthracycline therapy in the neoadjuvant or adjuvant setting, and had at least a 12-month disease-free interval since the end of their last cytotoxic therapy, were eligible for the study~* Participants who received prior hormonal therapy, or no more than 1 cytotoxic chemotherapy regimen (anthracyclines, taxanes, or antitubulin agents were not permitted), or both for advanced disease~* Participants with normal cardiac function, as evidenced by a normal left ventricular ejection fraction~Exclusion Criteria:~* More than 1 prior cytotoxic chemotherapy regimen for advanced breast cancer~* Treatment of advanced breast cancer with an anthracycline, paclitaxel, docetaxel, vinorelbine, or vinblastine (prior treatment of advanced breast cancer with 1 regimen that included alkylating agents or antimetabolite agents was acceptable)~* Less than 2 months since the last dose of trastuzumab~* Less than 3 weeks since last dose of tamoxifen or fulvestrant, or less than 1 week since the last dose of other hormonal therapy~* Radiation to areas of disease within 30 days before study enrollment~* History of New York Heart Association Class II or greater cardiac disease or other clinical evidence of congestive heart failure

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DOXIL and docetaxel combination therapy (Type: EXPERIMENTAL): DOXIL and docetaxel combination therapy: DOXIL 30 mg/m2 solution administered by intravenous infusion, followed by docetaxel 60 mg/m2 administration by intravenous infusion over 1 hour on Day 1 of every 21-day cycle.
- Docetaxel monotherapy (Type: ACTIVE_COMPARATOR): Docetaxel monotherapy: Docetaxel 75 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Investigation of Intravenous (IV) Administration of an Approved Drug (MK-0476, Montelukast Sodium) for Acute Asthma (MK-0476-288)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Individuals with acute asthma~Exclusion Criteria:~* Women of child bearing age~* History of Chronic Obstructive Pulmonary Disease (COPD)

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Montelukast 7 mg (Type: EXPERIMENTAL): Participants receive montelukast 7 mg intravenously (IV) until until a decision is made for one of the following: (1) discontinuation from the study, (2) discharge from the study site, or (3) admission to the hospital. All randomized participants will receive systemic corticosteroids (60 mg prednisone OR 50 mg prednisolone) orally immediately after the completion of the study drug administration. In addition, all participants will continue to receive standardized treatment in addition to study drug. Standardized treatment may consist of: (1) β-agonist administration beginning 20 minutes after study drug infusion, and every 20 minutes thereafter, as needed; (2) oxygen therapy; and (3) inhaled ipratropium every 60 minutes as needed.
- Placebo (Type: PLACEBO_COMPARATOR): Participants receive placebo IV until until a decision is made for one of the following: (1) discontinuation from the study, (2) discharge from the study site, or (3) admission to the hospital. All randomized participants will receive systemic corticosteroids (60 mg prednisone OR 50 mg prednisolone) orally immediately after the completion of the study drug administration. In addition, all participants will continue to receive standardized treatment in addition to study drug. Standardized treatment may consist of: (1) β-agonist administration beginning 20 minutes after study drug infusion, and every 20 minutes thereafter, as needed; (2) oxygen therapy; and (3) inhaled ipratropium every 60 minutes as needed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic Study of Oral Testosterone (T) Ester Formulations in Hypogonadal Men

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male, ages 18-68~* Serum total T less than or equal to 275 ng/dL~Exclusion Criteria:~* Significant intercurrent disease of any type, in particular, liver, kidney or heart disease, uncontrolled diabetes mellitus or psychiatric illness.~* Abnormal prostate digital rectal examination, elevated prostate-specific antigen (PSA), American Urological Association (AUA) symptom score of \>15, and/or history of prostate cancer.~* Hematocrit of \<35 or \>50%~* Body mass index (BMI) \>36~* Serum transaminases \> 2 times upper limit of normal or serum bilirubin \> 2.0 mg/dL

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 68 Years
- Healthy Volunteers: f

Study Arms:
- All study participants (Type: EXPERIMENTAL): Treatment Period 1: Three capsules each containing 100 mg testosterone (T) as testosterone undecanoate (TU), twice daily (BID) for 7 days.~Treatment Period 2: Two capsules each containing 200 mg T as TU and testosterone enanthate (TE), BID for 7 days.~Treatment Period 3: Two capsules each containing 100 mg T as TU, BID for 8 days.~Treatment Period 4: Two capsules each containing 150 mg T as TU and TE, BID for 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Confocal Endomicroscopy for Barrett's Esophagus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Barrett's esophagus or suspected Barrett's-associated neoplasia~* Age \> 18~* Able to give informed consent~Exclusion Criteria:~* Known advanced malignant disease~* Allergy to the fluorescent contrast agent fluorescein sodium~* Coagulopathy or bleeding disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CLE followed by standard EGD (Type: ACTIVE_COMPARATOR): Participants are randomized to have either confocal laser endomicroscopy (CLE) or standard endoscopy (EGD) first. Then 6 weeks later, they have the other procedure. This arm is for patients randomized to CLE followed by standard EGD
- standard EGD followed by CLE (Type: ACTIVE_COMPARATOR): Patients are randomized to either have standard endoscopy (EGD)or confocal laser endomicroscopy (CLE) first. The second procedure is then completed 6 weeks later. This arm is for patients who had standard endoscopy first.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multiple Treatment Study Using Low Field Magnetic Stimulation for Bipolar Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects will be men or women between the ages of 21-65.~2. Subjects must not have serious physical illnesses, neurological diseases or dementias.~3. Subjects will meet DSM-IV criteria for Bipolar Disorder Type I or II and meet criteria for current depression (DSM-IV major depressive episode, current).~4. Subject must have a MADRS \>= 20, Young Mania Rating Score (YMRS score) \< 7.~5. Subjects must be capable of providing informed consent.~6. Subjects must have an established residence and phone.~7. Subjects may be medicated or unmedicated.~Exclusion Criteria:~1. Dangerous or active suicidal ideation.~2. Pregnant or planning on becoming pregnant.~3. Substance abuse (cannot meet DSM criteria for substance abuse, no significant drug abuse within last 3 months, no major polysubstance abuse history, no history of dependence in last year, no drug use within last month).~4. Mania, hypomania or mixed mood state.~5. Significant medical or neurological illness that might pose a risk to study enrollment or interfere with interpretation of study data.~6. Changes in psychiatric medication (e.g. dose or drug) within 6 weeks prior to enrollment.~7. History of schizophrenia, schizoaffective, obsessive-compulsive or post-traumatic stress disorders.~8. Treatment resistant depression (as determined by the study psychiatrist; consistently and substantially symptomatic over several years despite electroconvulsive therapy, 2 or more adequate trials of a primary mood stabilizer with antidepressant effects (e.g., lithium, valproate or lamotrigine) or antidepressant medications (e.g., bupropion, Selective Serotonin Reuptake Inhibitors (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI).)~9. Contraindications for Magnetic Resonance Imaging (MRI): Presence of a pacemaker, neurostimulator, or metal in head or neck.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- LFMS - active treatment (Type: EXPERIMENTAL): Low Field Magnetic Stimulation (LFMS) active treatment~Active low field magnetic stimulation treatment applied with the LFMS Device; the device is on and magnetic field stimulation is present.
- LFMS - sham treatment (Type: SHAM_COMPARATOR): Low Field Magnetic Stimulation - sham treatment~Inactive low field magnetic stimulation (no stimulation) treatment applied with the LFMS Device; the device is on, however no magnetic field stimulation is present.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Relapsed/refractory diffuse large B cell lymphoma (DLBCL), relapsed/refractory peripheral T cell lymphoma (PTCL) (all subtypes excluding anaplastic large cell lymphoma), relapsed/refractory Cutaneous T cell lymphoma (CTCL) mycosis fungoides/sezary syndrome (MF/SS), relapsed/refractory primary mediastinal B lymphoma (PMBL), and relapsed/refractory mediastinal gray zone lymphoma (MGZL)~* Expression of CD30~* Subjects must be 18 years or older (≥ 15 years for PMBL)~Exclusion Criteria:~* Known central nervous system (CNS) lymphomas; Active cerebral/meningeal disease related to the underlying malignancy~* Active, known, or suspected autoimmune disease

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nivolumab+Brentuximab Vedotin (Type: EXPERIMENTAL): Nivolumab+Brentuximab Vedotin dose as specified

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Influence of Nonspecific Immunostimulation on Changes in the Concentration of iNKT Cells

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children of both genders aged 5 to 17 years.~* Children with grass pollen-induced allergic rhinitis recognized and treated according to current ARIA (Allergic Rhinitis and its Impact on Asthma) recommendations.~* Positive skin prick test to grass pollen allergens or positive specific IgE (defined as ≥ class 2, ≥ 0,70 kU/l) against timothy grass pollen allergens.~* Presentation of clinical symptoms of the allergic rhinitis (rhinorrhea, nasal congestion, nasal itching, sneezing) in at least two recent grass pollen seasons in Poland before inclusion in the study.~* Proper use of polyvalent mechanical bacterial lysate sublingual tablets.~* Not using drugs to alleviate the symptoms of allergic rhinitis in the last 7 days prior to enrollment in the study: intranasal glucocorticosteroids, intranasal, oral and ophthalmic antihistamines, intranasal and oral alpha-mimetics, intranasal anticholinergics, antileukotrienes and cromones.~* Written informed consent obtained from parents/guardians before any study related procedures are performed.~Exclusion Criteria:~* Patient received mechanical bacterial lysate immunostimulation within the previous 12 months before randomisation visit.~* Patient received chemical bacterial lysate immunostimulation within the previous 6 months before randomisation visit.~* Patient received oral/subcutaneous allergen-immunotherapy within the previous 3 years before the start of the study.~* Other chronic conditions of the nose or nasal sinuses.~* Severe nasal septum deviation.~* Acute respiratory infection in the 2 weeks prior to randomization visit.~* Treatment with systemic corticosteroids within the last 6 months before the start of the study.~* History of transfusion of blood, blood components or blood products.~* Pregnant or breastfeeding woman.~* Other chronic, uncontrolled diseases of the respiratory tract, gastrointestinal tract, urinary system, hematological diseases, immunodeficiency, cancer, cystic fibrosis.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Polyvalent mechanical bacterial lysate (Type: EXPERIMENTAL): Treatment over 3 successive months with one daily sublingual tablet (7 mg of bacterial lysate) over 10 days followed by 20 days of rest.
- Placebo (Type: PLACEBO_COMPARATOR): Treatment over 3 successive months with one daily sublingual tablet over 10 days followed by 20 days of rest.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Study With P2B001 in Subjects With Early Parkinson's

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject has Parkinson's disease consistent with the UK Brain Bank Criteria and must have bradykinesia with sequence effect. If rest tremor does not exist must have prominent asymmetry of motor function.~2. Subject with disease duration less than 3 years since diagnosis.~3. Subject has a H\&Y stage score of \< 3.~4. Subject has a MMSE score ≥ 26.~Exclusion Criteria:~1. Subject has an atypical parkinsonian syndrome or secondary parkinsonism~2. Subject has previous exposure to levodopa or a dopamine agonist for longer than 4 weeks; if previous exposure was less than 4 weeks then it must not be within 2 months prior to the baseline visit.~3. Subject has previous exposure to a MAO-B inhibitor for longer than 4 weeks; if previous exposure was less than 4 weeks then it must not be within 3 months prior to the baseline visit.~4. Subject who has taken anticholinergic drugs for PD or amantadine for longer than 4 weeks; if previous exposure was less than 4 weeks then it must not be within 1 month prior to the baseline visit.~5. Subject has moderate (Child-Pugh categorization B, score 7-9) or severe (Child-Pugh categorization C, score 10-15) hepatic impairment.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- P2B001 0.6/0.75 mg (Type: EXPERIMENTAL): Fixed dose combination once daily capsule of pramipexole 0.6mg and rasagiline 0.75mg, + matching placebo tablet
- rasagiline 0.75mg (Type: EXPERIMENTAL): Rasagiline 0.75mg Once daily capsule, component of P2B001, + matching placebo tablet
- Pramipexole 0.6mg (Type: EXPERIMENTAL): Pramipexole 0.6mg once daily capsule, component of P2B001 + matching placebo tablet
- Pramipexole Extended Release (Type: ACTIVE_COMPARATOR): Marketed pramipexole ER tablet titrated to optimal dose of 1.5, 3.0 or 4.5mg + matching placebo capsule

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete